Search

Displaying results 1491 - 1500 of 8468 in total
  1. Drug

    Ocrelizumab

    go.drugbank.com/drugs/DB11988
    ApprovedInvestigational

    [A31741] In September 2024, a formulation of ocrelizumab containing [hyaluronidase (human recombinant)] was approved by the US FDA. … Developed by Genentech/Roche, ocrelizumab was approved by the FDA in March 2017 under the market name Ocrevus for intravenous injection.

  2. Drug

    Artenimol

    go.drugbank.com/drugs/DB11638
    ApprovedInvestigational

    It was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim.

  3. Drug

    Selenium Sulfide

    go.drugbank.com/drugs/DB00971
    Approved

    Selenium Sulfide is an antifungal agent as well as a cytostatic agent, slowing the growth of hyperproliferative cells in seborrhea.

  4. Drug

    Adenine

    go.drugbank.com/drugs/DB00173
    ApprovedInvestigationalNutraceutical

    A purine base and a fundamental unit of adenine nucleotides.

    Mixtures: As 3, As-3
  5. Drug

    Rolicyclidine

    go.drugbank.com/drugs/DB01549
    ExperimentalIllicit

    Rolicyclidine (PCPy) is classified as a dissociative anesthetic agent. It also has hallucinogenic and sedative properties. … Because of its pharmacodynamic similarity to the drug phencyclidine (PCP), rolicyclidine was added to the Schedule I list of illegal drugs in the USA in the 1970s.

  6. Drug

    Crizotinib

    go.drugbank.com/drugs/DB08865
    ApprovedInvestigational

    Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic … [A250785] Crizotinib was the first-in-class drug used to treat ALK-positive tumors.

  7. Drug

    Rifampin

    go.drugbank.com/drugs/DB01045
    ApprovedInvestigational

    Rifampin, also known as rifampicin, is a broad-spectrum antimicrobial [A263748] that was first discovered in 1965 [A263753] and clinically used in 1968.

  8. Drug

    Myrrh

    go.drugbank.com/drugs/DB11605
    ApprovedInvestigational

    Extractives and their physically modified derivatives such as tinctures, concretes, absolutes, essential oils, oleoresins, terpenes, terpene-free fractions, distillates, residues, obtained from Commiphora

  9. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    [L45300] On April 24, 2024, sparsentan was granted conditional marketing authorization by the European Commission for the treatment of adults with primary IgAN.[L51559] … [L45300,L45315] In September 2024, it was granted full approval for an expanded indication.

  10. Drug

    Novobiocin

    go.drugbank.com/drugs/DB01051
    ApprovedInvestigationalVet approvedWithdrawn

    (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189) Novobiocin sodium, a salt form of novobiocin, was initially approved in September 1964 and was indicated for the treatment of serious … In 2009, the FDA determined novobiocin sodium was withdrawn from sale for reasons of safety or effectiveness.[L44062,L43942]